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real-time PCR in BM aspirates of 46 MM patients, four 
patients with monoclonal gammopathy of undetermined sig-
nificance, five solitary plasmacytomas, and five healthy BM 
donors. Gene expression was evaluated regarding an influ-
ence on the patients’ overall survival (OS).
Results FOXP3 and CTLA4 presented a sixfold (p = 0.02) 
and 30-fold higher expression (p = 0.03), respectively, 
in MM patients than in controls. RORγt expression was 
similar in MM patients and controls. Median OS of MM 
patients was 16.8 (range 4.5–29.1) months, and interna-
tional staging system was the only independent prognostic 
factor for patients survival.
Conclusions Overexpression of FOXP3 and CTLA4 in 
total BM samples suggests a local accumulation of immu-
nosuppressive Tregs, the MM tumor environment, possibly 
dampening anti-tumor host immune responses. Therapeu-
tic approaches targeting Treg cells and restoring local anti-
tumor immunity may provide new treatment strategies for 
this incurable malignancy.
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Abbreviations
BM  Bone marrow
CTLA4  Cytotoxic T lymphocyte-associated antigen 4
FOXP3  Member of the forkhead/winged helix family
IL  Interleukin
iTreg  Induced Treg
ISS  International staging system
MGUS  Monoclonal gammopathy of undetermined 
significance
MM  Multiple myeloma
nTreg  Natural Treg
OS  Overall survival
Abstract 
Introduction Multiple myeloma (MM) development 
involves a series of genetic abnormalities and changes in 
the bone marrow (BM) microenvironment, favoring the 
growth of the tumor and failure of local immune control. 
T regulatory (Treg) cells play an important role in dampen-
ing anti-tumor immune responses while T-helper-17 (Th17) 
cells seem to be critical for the eradication of malignant 
cells. The aim of our study was to characterize the expres-
sion of Treg- and Th17-related genes in total myeloma 
BM samples to assess their role as biomarkers, prognostic 
factors, and possible therapeutic targets in this incurable 
disease.
Methods Expression of markers for Treg (FOXP3, CTLA4) 
and Th17 cells (RORγt) was determined by quantitative 
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qPCR  Quantitative real-time PCR
RUNX1  Runt-related transcription factor 1
RORγt  Orphan nuclear receptor γt
SP  Solitary plasmacytoma
STAT 3  Signal transducer and activator of transcription 3
TCR  T cell receptor
Teff  T effector cells
TGFβ  Transforming growth factor β
Th1  T-helper 1
Th2  T-helper 2
Treg  T regulatory
Th17  T-helper-17
Introduction
Multiple myeloma (MM) development involves a series 
of genetic abnormalities and changes in the bone marrow 
(BM) microenvironment, favoring the growth of the tumor 
and the failure of local immune control. Cellular immune 
defects in MM include decreased number of CD19+ B cells 
as well as CD4+ and CD8+ T cells. The presence of these 
abnormalities seems to negatively correlate with survival, 
indicating a potential relationship between cellular immune 
components and disease control [1]. A significant impair-
ment of T cell function has been described for MM patients 
and for patients with monoclonal gammopathy of undeter-
mined significance (MGUS) [2].
Subpopulations of CD4+ T cells, such as T regulatory 
(Treg) and T-helper-17 (Th17) cells, have emerged as a 
key players in the immune control of cancer. Represent-
ing 5–10 % of all CD4+ T cells in the peripheral blood, 
Tregs express CD4 and CD25 surface antigens as well 
as cytoplasmic (cytotoxic T lymphocyte-associated anti-
gen 4) CTLA4 and GITR. Treg cells control many facets 
of immune responses in an attempt to maintain immune 
homeostasis, ranging from autoimmune diseases to inflam-
matory conditions and cancer. Two major Treg popula-
tions have been reported to date. Natural Treg (nTreg) cells 
develop in the thymus and constitute a critical arm of active 
mechanisms of peripheral tolerance, particularly to self-
antigens. A growing body of knowledge supports the exist-
ence of induced Treg (iTreg) cells, which may derive from 
conventional CD4+ T cells. CD4+ T cells are induced by 
IL-10 and secrete both IL-10 and transforming growth fac-
tor β (TGFβ) converting peripheral naïve CD4+ CD25− 
FOXP3− cells to FOXP3-expressing cells. Regardless 
of their origin, they share one key feature: their ability to 
potently suppress effector T cells (Teff). This suppressive 
activity of Treg cells is associated with the overexpression 
of FOXP3, a member of the forkhead/winged helix family, 
which acts as a transcriptional repressor [3], and CTLA4, a 
coinhibitory molecule that maintains immune homeostasis 
by down regulating T cell-related costimulatory pathways. 
FOXP3-expressing cells in cancer settings have been cor-
related with poor anti-tumor effector response, hence com-
promising tumor immunity [4, 5].
Currently, many studies are focusing on Treg popula-
tions in MM, and a lot of controversy has been found in 
this field. While Prabhala et al. [2] showed an increase in 
CD4+ CD25+ in peripheral blood and BM of monoclonal 
gammopathy of undetermined significance (MGUS) and 
MM patients when compared with controls, they also found 
that Treg cells—evaluated by FOXP3 expression—are sig-
nificantly decreased in number and function in patients 
with MGUS and MM compared with healthy donors. In 
other study, Gupta et al. [6] reported a decrease in fre-
quency of Treg as well as reduced expression of FOXP3 
by flow cytometry in peripheral blood samples of untreated 
MM patients, which increased significantly after treatment 
with thalidomide. Furthermore, Treg MM cells exhibited 
immunosuppressive activity in vitro [6]. On the other hand, 
Beyer et al. [7] demonstrated in both MGUS and MM that 
functional FOXP3+ Treg cells of naive, central, and effec-
tor memory phenotype (evaluated by CCR7 and CD45RA 
expression) are significantly expanded. The last study was 
supported by Feyler et al. [8] that showed significantly 
elevated levels of functional CD4+ CD25+ FOXP3+ Treg 
cells obtained from peripheral blood samples and analyzed 
by flow cytometry in MGUS and MM in comparison with 
healthy controls.
Th17 cells, a recently described IL-17-expressing CD4+ 
T cell subset, protect hosts against fungal and parasitic 
infections and participate in inflammatory reactions and 
autoimmunity. One of the main Th17-specific transcription 
factors is the orphan nuclear receptor, RORγ. Its specific 
isoform RORγt is selectively expressed by Th17 cells and 
regulated by STAT3. Overexpression of RORγt promotes 
Th17 differentiation while inhibiting Th1 and Th2 develop-
ment [9, 10]. The role of Th17 cells in tumor pathogenesis 
is still not well defined. However, it seems that the balance 
between Treg and Th17 cells is particularly important for 
maintaining the homeostasis of anti-tumor immunity [11]. 
FOXP3 plays a negative role in IL-17 expression through 
physical interaction with RUNX1 and RORγt, thereby 
inhibiting their transactivation activity. RUNX1 is highly 
expressed in CD4+ T cells as well as FOXP3+ Tregs and 
interaction between RUNX1 and FOXP3 is essential for 
FOXP3 function. RUNX1 also has a significant role in 
Th17 differentiation due to its ability to induce RORγt 
expression and to associate with and to act together with 
RORγt to induce IL17 transcription [12].
Increased number of Th17 cells in MM BM in com-
parison with peripheral blood has also been described. 
Dhodapkar et al. [13] demonstrated that the proportion of 
Th17 cells in the BM of MM patients was higher than in 
1191Cancer Immunol Immunother (2014) 63:1189–1197 
1 3
peripheral blood samples. Moreover, functional proper-
ties varied according to compartment: MM BM samples 
contained a significantly higher proportion of polyfunc-
tional Th17-1 cells than peripheral blood, and these cells 
were not observed in MGUS BM samples. IL-6, TGFβ, 
and IL-1 play an important role in MM immune dysfunc-
tion. Since IL-6 and TGFβ are also important for the gen-
eration of Th17 cells, Prabhala et al. [11] observed a sig-
nificantly elevated baseline and induced frequency of Th17 
cells in peripheral blood and BM from MM patients com-
pared with controls. They confirmed a significant increase 
in IL-17, IL-21, IL-22, and IL-23 serum levels in blood 
and BM in MM compared with healthy controls and that 
IL-17 promotes MM cell growth and colony formation via 
IL-17 receptor, adhesion to BM stromal cells and increased 
growth in the in vivo murine xenotransplant model of 
human MM cell lines. The authors concluded that Th17 
cells play an important role in MM pathobiology and may 
be an important therapeutic target for anti-tumor effect 
[11].
In this scenario, we believe that the balance between 
Treg and Th17 cells is important in the BM of MM. Also, 
exploring this concept may be more relevant than previous 
results that used exclusively peripheral blood samples or 
analyses only one of these CD4+ populations. Therefore, 
the aim of this study was to simultaneously characterize 
the expression of Treg (FOXP3 and CTLA4)- and Th17 
(RORγt)-related genes in total MM BM samples in order 
to assess the local immune milieu as potential biomarker/
therapeutic target and to understand whether these genes 
have a prognostic impact on this incurable disease.
Materials and methods
Patients
Forty-six newly diagnosed MM patients referred to the 
Hematology and Hemotherapy Service of Federal Univer-
sity of São Paulo (UNIFESP) in São Paulo, Brazil were 
collected between 2003 and 2012. Only patients with no 
previous chemotherapy, corticosteroid, or bisphosphonate 
treatment were included. The diagnosis of MM was based 
on The International Working Group Criteria [14], and 
information on tumor stage was obtained for all patients 
according to Durie–Salmon and the international staging 
system (ISS) [15]. According to the ISS, 6 cases were clas-
sified as stage I, 13 as stage II, 23 as stage III, and 4 cases 
could not be classified because of the absence of beta2-
microglobulin data (Table 1). Patients were treated with 
dexamethasone/thalidomide or melphalan/prednisone/tha-
lidomide, depending on their age and performance status, 
and 5 patients also received high-dose melphalan followed 
by autologous stem cell transplantation. We also studied 
BM aspirates from 4 patients with MGUS, 5 patients with 
solitary plasmacytoma (SP), and 5 healthy BM donors 
(not age matched with patients’ group). Written informed 
consent was obtained from all patients and controls, and 
the study was approved by the Ethical Committee of this 
institution.
Magnetic sorting of CD138-positive cells
BM samples were collected in sterile EDTA tubes during 
routine diagnostics, and neoplastic plasma cells were sep-
arated by magnetic sorting of CD138-positive cells using 
the MACS system (Magnetic Cell Sorting of Human Cells; 
Miltenyi Biotec, Bergisch-Gladbach, Germany), according 
to previous descriptions [16].
Flow cytometry
For the analysis of Treg cells in total BM, the flow through 
(after CD138+ sorting) cells of 13 MM, 1 SP, 2 MGUS 
patients, and 3 healthy donors were stained with allophyco-
cyanin (APC)-H7-Clone SK7-labeled anti-CD3, peridinin–
chlorophyll–protein complex (PerCP)-Clone SK3-labeled 
anti-CD4 and fluorescein isothiocyanate (FITC)-M-Clone 
A251-labeled anti-CD25 antibodies (BD Biosciences, 
NSW, Australia). Intracellular labeling with PE-conjugated 
Table 1  Multiple myeloma characteristics at diagnosis (N = 46)
D&S Durie–Salmon classification, ISS international staging system, 
NA not available
Characteristics
Median age, years (range) 66 (27–95)
Sex, n (%)
Male 25 (54)
Female 21 (46)
Type of M-protein, n (%)
IgA 09 (20)
IgG 25 (54)
IgM 01 (02)
Light chain disease 04 (09)
NA 07 (15)
D&S stage, n (%)
I 02 (04)
II 01 (02)
III 43 (94)
ISS
1 06 (13)
2 13 (28)
3 23 (50)
NA 04 (09)
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anti-FOXP3-Clone 236a/E7 and anti-CTLA4-APC-Clone 
BNI3 was followed by permeabilization with fix/perm 
solution according to the manufacturer’s protocol (BD 
Biosciences). Flow cytometry was carried out using a BD 
FACScanto II (BD Biosciences), and lymphocytes were 
gated based on their forward and side light scatter proper-
ties. Data were analyzed with Infinicyt software (Cytognos 
SL, Salamanca, Spain). After gating the lymphocyte popu-
lation, CD3+CD4+CD25highFOXP3+CTLA4+ populations 
showing a Treg phenotype were sequentially gated and 
analyzed [17, 18]. Proportional numbers of Treg cells were 
calculated from target cell frequency as determined by flow 
cytometry and total lymphocyte counts calculated during 
routine diagnostics.
RNA extraction
RNA extraction from mononuclear cells (MNC) derived 
from total BM was performed as previously described [19]. 
Expression of genes related to the Treg and Th17 subpopu-
lations, respectively, was evaluated by quantitative real-time 
PCR (qPCR) using 7500 Real Time PCR System (Applied 
Biosystems, Foster City, CA). Commercially available 
qPCR assays were used: FOXP3 (Hs01085834_m1*), 
CD25 (Hs00907779_m1*), TGFβ1 (Hs00998133_m1*), 
CTLA4 (Hs03044418_m1*), RORyt (Hs01076112_m1*), 
IL6 (Hs00985639_m1*), and IL-17A (Hs00174383 m1*).
Expression of target genes was normalized by the arith-
metic mean of triplicates of housekeeping genes (ACTβ and 
GAPDH) [19]. Samples containing no cDNA were used as 
negative controls. All samples were analyzed in triplicate. 
The relative mRNA expression level of the target genes 
was calculated using the 2−ΔΔCT method [20]. Genes were 
considered differentially expressed in tumor samples when 
their expression levels showed at least a twofold increment 
or decrease in comparison with normal samples.
Statistical analysis
Associations between the variables were tested by the 
Pearson’s chi-squared test (χ2). The Mann–Whitney test 
was used to compare two individual values. Pearson’s 
product-moment correlation coefficient (Pearson’s r) was 
used to measure the strength of linear dependence between 
two variables. Overall survival (OS) was calculated from 
the date of diagnosis of MM until death or last follow-up. 
Actuarial probabilities of OS were estimated according to 
the Kaplan–Meier method, and the curves were compared 
using the log-rank test. Cox’s regression model was also 
employed to evaluate which variables could be considered 
independent prognostic factors. Differences with a p < 0.05 
were regarded as statistically significant. Statistical analy-
ses were performed using SPSS Software version 14.0 
(SPSS Inc., Chicago, IL) and Prism 5 software (GraphPad, 
San Diego, CA).
Results
The present study aimed at describing the bone marrow 
environment of MM with regard to the presence of Tregs 
and Th17 cells. Determining the frequency of these immu-
nomodulating T cell subtypes in whole BM could theoreti-
cally be hampered by expression of the respective marker 
genes by tumor cells themselves. Therefore, in a first step, 
we checked whether FOXP3, CTLA4, and RORyt were 
aberrantly expressed by malignant plasma cells. The results 
showed a 125-fold lower FOXP3 expression (p = 0.0001), 
Fig. 1  Relative expression (2−ΔΔCT) of FOXP3, CTLA4, and RORyt 
in sorted plasma cells and their respective total bone marrow aspi-
rates by qPCR. Pilot study with 10 MM cases shows that Treg and 
Th17 genes were not significantly expressed by plasma cells, with the 
exception of one outlier (arrows) for CTLA4 and RORyt
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52-fold lower CTLA4 expression (p = 0.003), and almost 
undetectable RORyt expression (p = 0.005) when plasma 
cells samples were compared to total BM (Fig. 1). These 
data are in agreement with Oncomine cancer profiling data-
base (www.oncomine.org). Therefore, we concluded that 
the genes analyzed in this study are indeed not expressed 
by BM-infiltrating myeloma cells, and their expression in 
whole BM is mainly determined by the local presence of 
Tregs and Th17 cells.
Next, we analyzed whether real-time PCR would be 
as useful for quantification of immunomodulating T cell 
subsets as flow cytometry (considered the gold standard 
method in most of the previous studies). Applying both 
methods to 19 BM samples (13 cases of MM, 1 SP, and 
2 MGUS patients), as well as 3 healthy donors, we found 
a linear correlation (r = 0.48; p = 0.03) between the pro-
portion of Tregs (CD3+CD4+CD25highFOXP3+CTLA4+) 
in total BM samples as determined by flow cytometry and 
the expression of CTLA4 assessed by qPCR (Figs. 2, 3a and 
Supplementary Figure 1).
Having shown that real-time PCR is useful to quantify 
Tregs and Th17 cells in whole BM samples from mye-
loma patients, we applied this approach to all samples 
collected. Treg-related gene FOXP3 was overexpressed in 
68 % of individual MM cases, and overall expression was 
6.1-fold higher (p = 0.02) in MM patients when compared 
to healthy donors (Fig. 4a). CTLA4 was overexpressed 
in 76 % of individual MM cases, and overall expression 
was 30-fold higher when compared to controls (p = 0.03) 
(Fig. 4b). A strong linear correlation was observed between 
the expression of genes FOXP3 and CTLA4 (Pearson’s’ 
r = 0.83 and p < 0.0001) (Fig. 3b). In contrast, expression 
of RORγt was not different when MM patients and healthy 
controls were compared (Fig. 4c). We also analyzed BM 
expression of other genes related to Treg and Th17 cell sub-
populations. However, BM expression levels of CD25, IL6, 
and TGFβ1 were equivalent in MM patients and healthy 
controls. IL-17 showed no expression in normal or MM 
BM aspirates using two different primer sequences. Median 
OS of MM patients was 16.8 months (range 4.5–29.1). 
Univariate analysis indicated that none of the CD4+ T cell-
related genes but only ISS (p = 0.011) had impact on the 
patients’ prognosis, a finding confirmed by Cox regression 
analysis (p = 0.011, RR 5.04, CI 1.15–22.11) (Table 2).
Discussion
In this study, we observed the overexpression of FOXP3 
and CTLA4 in the BM of myeloma patients when com-
pared to healthy controls. In contrast, Th17-related genes 
were not differentially expressed in the BM of patients with 
MM. The virtual absence of FOXP3 and CTLA4 expres-
sion in myeloma cells and the linear correlation of CTLA4 
gene expression with that of BM-infiltrating Tregs by flow 
cytometry led us to believe that most of the expression of 
Treg-related genes in myeloma BM aspirates might be due 
to the presence of the immunosuppressive CD4+ T cell 
subpopulation in tumor microenvironment.
Therefore, our finding of an increased expression of 
FOXP3 and CTLA4 in BM of MM patients suggests an 
accumulation of immunosuppressive Tregs in the tumor 
microenvironment of myeloma patients. We believe that 
local accumulation of Tregs in the lack of major changes 
in Th17 gene expression could contribute to the immune 
imbalance in MM. Of note, accumulating evidence indi-
cates that Th17 cells may provide protection against malig-
nancies by inducing Th1-type chemokines and recruiting 
effector cells to the tumor site [21]. Tregs, on the other 
hand, are believed to maintain immunologic tolerance to 
tumor cells by suppressing the activation and expansion of 
self-reactive immune cells [22, 23].
We thought to use total BM as the source of samples 
for this study since our institution has RNA bank availa-
ble and the study of the T cell compartment inside tumor 
BM environment, without manipulation of CD4 subpopu-
lations by sorting looked appealing. A pilot study using 
ten sorted plasma cells samples (and their respective total 
Fig. 2  Multiparameter flow cytometry analysis showing CD4+ 
CD25high immunophenotype in bone marrow aspirate samples from 
a case of multiple myeloma (a) and a healthy donor (c) (indicated 
as color dots); FOXP3+CTLA4(CD152) positive (color dots) in the 
same myeloma sample (b) and negative in the same healthy donor 
sample (D)
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BM) supported the hypothesis that MM tumor cells are not 
responsible for Treg- or Th17-related genes expression. 
The small amount of FOXP3, CTLA4, or RORyt detected 
(including one outlier for the last two genes) in plasma 
cells samples could be related to “contamination” of sorted 
cells with BM T cells.
Despite FOXP3 being considered the most specific 
marker for naturally occurring CD4+ CD25+ Tregs, divid-
ing activated T effector cells (Teff cells) can express 
FOXP3 transiently, and at significantly lower levels than 
suppressive Tregs [24]. Therefore, in this study, FOXP3 
transcripts were attributed, not exclusively but mostly, to 
Tregs in total BM.
To validate further gene expression studies, we ana-
lyzed 19 samples by both qPCR and flow cytometry, in 
which the flow through (after CD138+ sorting) was also 
available. While there is a linear correlation between the 
proportion of Treg cells/total lymphocytes in BM samples 
by flow cytometry and CTLA4 expression by qPCR in 19 
samples, it is also clear that for three of the 16 samples 
(one MM and 2 MGUS/PS) qPCR and flow cytometry 
data do not correlate. One possible explanation lies on 
gene expression regulation both at the transcriptional level 
and at the posttranscriptional level by posttranslational 
modifications.
There are a number of studies that have used FOXP3 
qPCR as a surrogate for Tregs, with or without previ-
ous CD4-positive population sorting [25–27] or RORyt 
as a surrogate marker of Th17 population [13]. Liu et al. 
[25] used a similar approach to compare qPCR and flow 
cytometry adopted in Fig. 3a, to correlate the percentage 
of demethylation of FOXP3 by real-time PCR and the one 
of CD4+ CD25hi T cells by flow cytometry in cord blood 
mononuclear cells.
Fig. 3  a Linear correlation between the proportion of Treg cells/total 
lymphocytes in BM samples by flow cytometry and CTLA4 (CD 152) 
expression by qPCR in 19 samples: 13 cases of MM, 1 SP, 2 MGUS 
patients, and 3 normal controls. b Linear correlation between expres-
sion of FOXP3 and CTLA4 in 46 bone marrow aspirates of multiple 
myeloma (MM) by qPCR
Fig. 4  a Relative expression (2−ΔΔCT) of FOXP3 in bone mar-
row aspirates of multiple myeloma (MM), solitary plasmacyto-
mas (SP), monoclonal gammopathy of undetermined significance 
(MGUS) patients and normal controls by qPCR. b Relative expres-
sion (2−ΔΔCT) of CTLA4 in bone marrow aspirates of multiple mye-
loma (MM), solitary plasmacytomas (SP), monoclonal gammopathy 
of undetermined significance (MGUS) patients and normal controls 
by qPCR. c Relative expression (2−ΔΔCT) of RORyt in bone marrow 
aspirates of multiple myeloma (MM), solitary plasmacytoma (SP), 
monoclonal gammopathy of undetermined significance (MGUS) 
patients and normal controls by qPCR
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It is important to consider that the obtaining of an 
“ideal” bone marrow healthy donor is a challenge in this 
type of study, where the median age of MM patients was 
66 years old, ranging from 27 to 95 years. Therefore, in the 
absence of a better alternative, we used healthy controls 
that were not age matched, recruited after informed consent 
among bone marrow donors for allogeneic transplant. We 
can see in Fig. 4b that there is a significant difference in 
CTLA4 expression between MGUS/PS and MM independ-
ent of the age of controls.
The majority of patients in our study was diagnosed 
with advanced disease (stage III of Durie & Salmon: 94 % 
and ISS 2/3: 78 %) and, despite a significant increase in 
the expression of genes related to Treg cells, this had no 
impact on MM OS. Unfortunately, advanced stage MM is 
part of the reality of all public hospitals in Brazil. In a mul-
ticenter study, Hungria et al. [28] found 76.5 % of Durie 
and Salmon stage III MM cases and 79.9 % ISS 2/3 among 
1066 analyzed patients.
In the survival analysis illustrated in Table 2, the mark-
ers are scored in three categories, using the same cutoffs 
defined for gene expression analyses (twofold increment 
or decrease in comparison with normal samples). Unfor-
tunately, the small number of samples analyzed, and the 
treatment heterogeneity (only five patients were eligible for 
autologous stem cell transplantation) also could reduce the 
chances of achieving a correlation between the expression 
of the studied genes and clinical outcome.
However, recent studies addressed this topic using dif-
ferent methods and could demonstrate that the percentage 
of Treg cells isolated from peripheral blood and or bone 
marrow could have impact in MM outcome. In Giannopou-
los et al. [23] study, patients were divided into two cohorts 
according to median Treg frequency. Those with a high per-
centage of Treg lived significantly less (median overall sur-
vival [OS] of 21 months) as compared with those with lower 
Treg frequency (median OS not reached at median follow-up 
of 32 months). The difference in survival was also observed 
when only non-transplanted patients were analyzed. On the 
other hand, patients submitted to autologous transplant pre-
sented no difference in OS when both groups of Treg fre-
quencies were compared [29]. Raja et al. [30] evaluated Treg 
cells in both peripheral blood and bone marrow in a larger 
number of cases of MM using flow cytometry. They found 
a significantly elevated frequency of Treg cells in a newly 
diagnosed and relapsed MM patients compared with healthy 
controls. Functional studies showed that Treg cells from both 
MM and controls were similar in their inhibitory function. 
Using cutoffs very close to Giannopoulos et al. group [23], 
they showed that MM patients with high percentage of Treg 
cells had inferior time to progression and this variable had 
independent prognostic impact by multivariate analysis [30].
Unfortunately, our study could not confirm the above results 
using two Treg-related gene expressions.
In this study, we also analyzed BM expression of other 
genes related to Treg and Th17 cell subpopulations. How-
ever, BM expression levels of CD25 and TGFβ1 (Treg-
related genes) were equivalent in MM patients and healthy 
controls, and IL-17 (Th17-related gene) showed no expres-
sion in normal or MM bone marrow aspirates using two 
different primer sequences. The results were positive only 
after PCR product reamplification by qPCR. To avoid dis-
crepancies with the expression of other genes, we decided 
to use only RORyt as a surrogate (and more reliable) marker 
for Th17. However, it failed to detect any abnormality when 
normal samples were compared to MM BM aspirates.
An imbalance between Treg and Th17 cells comparable to 
the one we have observed in the BM of our MM patients has 
been previously demonstrated in the tumor microenvironment 
of other malignancies. For example, one study in gastric can-
cer showed an increased number of Th17 cells as well as Treg 
in the tumor microenvironment in early stages of the disease. 
With progression of the cancer, tumor infiltration by Th17 cells 
gradually decreased while numbers of Tregs increased [31]. It 
is important to emphasize that Treg and Th17 developmental 
programs are reciprocally interconnected: upon T cell recep-
tor (TCR) stimulation, naive T cells can be driven to express 
FOXP3 and become Tregs, if TGFβ is present. However, in 
the presence of TGFβ plus IL-6 or IL-21, the developmental 
pathway of Tregs is abrogated, and instead, T cells develop 
into Th17 cells. Only the combination of TGFβ plus IL-6 and 
IL-21, but neither one of them alone, induces a robust produc-
tion of IL-17 by naive T cells [32, 33]. Therefore, IL-6 plays a 
Table 2  Univariate analysis: overall survival according to ISS, 
FOXP3, CTLA4, and RORyt expression
NA not available
Factor N (%) Median OS (months) p value
ISS 0.011
1 06 (13) 36.3
2 13 (28) 42.3
3 23 (50) 5.4
FOXP3 0.690
Underexpressed 07 (15) 3.0
Normal expression 08 (17) 29.0
Overexpressed 31 (67) 16.8
CTLA4 0.817
Underexpressed 06 (13) 36.3
Normal expression 05 (11) 19.9
Overexpressed 35 (76) 11.6
RORyt 0.447
Underexpressed 21 (46) 16.8
Normal expression 13 (28) 29
Overexpressed 12 (26) 2.5
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pivotal role in dictating the balance between the generation of 
Tregs and Th17 cells as indicated by the FOXP3/RORγt ratio 
[5, 34]. Based on the well-known fact that in myeloma, IL-6 is 
produced in an autocrine and paracrine fashion and promotes 
the survival and progression of tumor cells; we had expected 
that the induction of Th17 would have been favored in this 
malignancy [35]. However, it seems that in MM other fac-
tors are involved instead to promote the local accumulation of 
Tregs and not the development of Th17 cells.
In the opposite direction of our findings, there is also an 
interesting study in a humanized murine model, showing 
that ex vivo-cultured human Tregs do not suppress anti-
tumor immunity in BM, but only if the tumor is located 
outside the BM [34]. Again, using the Treg/Th17 recipro-
cally interconnected theory, the authors demonstrated that 
BM stromal cells reverse the suppressive activity of Tregs 
and promote IL-17 expression in these cells via IL-1β and 
IL-6 production. Therefore, the authors feel skeptical about 
the benefits of future Treg-based therapies [36]. Also, BM 
stromal cell may have an important role in maintaining 
Treg/Th17 interconnection in MM.
In conclusion, our current study suggests an accumu-
lation of immunosuppressive Tregs in tumor microenvi-
ronment of myeloma patients by an overexpression of 
FOXP3 and CTLA4. Even in a still controversial scenario, 
we believe that this finding could bring new insights about 
possible biomarkers and therapeutic targets for MM. Mon-
oclonal antibodies targeting CTLA4, such as ipilimumab, 
should be evaluated in myeloma as they have been, for 
example, in melanoma [5]. Alternatively, the depletion of 
Treg cells, with a possible “reprogramming” of these cells 
to pro-inflammatory cells, could be a strategy of immuno-
therapy against human malignancies such as MM [37].
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